DanCann Pharma A/S: Agreement Reached on Permanent Medicinal Cannabis Scheme in Denmark

COPENHAGEN, Denmark, 29 November 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, is pleased to announce that the Danish Government (comprising Socialdemokratiet, Venstre og Moderaterne) and Socialistisk Folkeparti, Liberal Alliance, Danmarksdemokraterne, Enhedslisten, Dansk Folkeparti and Alternativet, have reached an agreement on 28 November 2024 to make the current Pilot Programme for medicinal cannabis permanent.

A Permanent Framework for Medicinal Cannabis

Under this permanent scheme, patients experiencing positive outcomes from medicinal cannabis treatments will continue to have access to prescriptions from their doctors. This framework reinforces patient safety by enabling general practitioners to prescribe medicinal cannabis within a legal and regulated environment, mitigating the risks associated with patients turning to the illegal cannabis market. This agreement secures patients’ access to medicinal cannabis under structured healthcare system conditions.

The agreement ensures that patient reimbursement for purchasing medicinal cannabis will continue in their current form under the permanent scheme.

Updated Medicinal Cannabis Guidelines

The Danish Medicines Agency (Lægemiddelstyrelsen) will update its medicinal cannabis guidelines before the permanent scheme takes effect. These updates will incorporate knowledge about side effects gained during the Pilot Programme, providing a more robust foundation for physicians to prescribe medicinal cannabis with greater confidence. Additionally, a concise patient summary (“pixie guide”) will be developed, enabling physicians to share essential information about the legal alternatives available through medicinal cannabis prescriptions.

Acknowledging that a lack of awareness among physicians can act as a barrier to prescribing medicinal cannabis, the agreement includes distributing the updated guidelines to general practitioners to enhance their understanding of the scheme.

The Minister of the Interior and Health has also tasked the Danish Patient Safety Authority (Styrelsen for Patientsikkerhed) with reviewing and updating the medical grounds for its recommendation on driving restrictions for patients undergoing medicinal cannabis treatment, potentially incorporating insights from other countries.

Enhanced Industry Opportunities

The agreement also allows for importing medicinal cannabis cultivated in other EU countries for further processing under an Active Pharmaceutical Ingredient (API) scheme. Additionally, the Danish Medicines Agency’s guidance for Danish cannabis producers will be improved to reduce processing times and facilitate smoother operations.

Ongoing Knowledge Sharing

To ensure continued collaboration and knowledge sharing, the reference group for medicinal cannabis will be extended through 2025 and 2026. DanCann Pharma is represented through its membership in the Medicinsk Cannabis Industri (MCI), where the Company’s CEO, Jeppe Krog Rasmussen, serves as Vice Chairman of the interest organization.

Legislative Implementation

The current Pilot Programme for medicinal cannabis is set to expire at the end of 2025. The transition to a permanent scheme will require legislative approval, and the agreement’s signatories have committed to voting in favor of the proposed legislation.

CEO of DanCann Pharma, Jeppe Krog Rasmussen, comments:

“We are pleased to see the foundation of our business - and the basis for so many patients’ treatment with medicinal cannabis - now firmly established. The risk that the Pilot Programme might be discontinued has finally been eliminated. This provides much-needed certainty and stability for businesses, patients, and physicians within and around the industry.

We look forward to seeing the final adjustments in the legislative text and hope that the government and supporting parties have carefully considered the input provided by stakeholders. It is our hope that they will take this opportunity to make the necessary refinements to create the best possible framework for delivering effective solutions to the patients relying on this type of treatment.”

For more information, please see: https://www.ism.dk/nyheder/2024/november/ny-aftale-ordning-med-medicinsk-cannabis-paa-recept-bliver-permanent  

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO

E-mail: jkr@dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.